With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Conditions are getting a bit more challenging for the drugmaker.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Eli Lilly is studying two weight loss candidates in phase 3 trials ... A small player like Viking may also win by attracting ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Currently, two innovators are dominating the $50 billion market : Novo Nordisk’s Ozempic or Wegovy (Semaglutide) and Eli ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...